JP2015518903A5 - - Google Patents

Download PDF

Info

Publication number
JP2015518903A5
JP2015518903A5 JP2015516256A JP2015516256A JP2015518903A5 JP 2015518903 A5 JP2015518903 A5 JP 2015518903A5 JP 2015516256 A JP2015516256 A JP 2015516256A JP 2015516256 A JP2015516256 A JP 2015516256A JP 2015518903 A5 JP2015518903 A5 JP 2015518903A5
Authority
JP
Japan
Prior art keywords
compound
acceptable salt
pharmaceutically acceptable
optionally substituted
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015516256A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518903A (ja
JP6214643B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/044800 external-priority patent/WO2013185084A1/en
Publication of JP2015518903A publication Critical patent/JP2015518903A/ja
Publication of JP2015518903A5 publication Critical patent/JP2015518903A5/ja
Application granted granted Critical
Publication of JP6214643B2 publication Critical patent/JP6214643B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015516256A 2012-06-08 2013-06-07 ピリミジニルチロシンキナーゼ阻害剤 Expired - Fee Related JP6214643B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261657360P 2012-06-08 2012-06-08
US61/657,360 2012-06-08
PCT/US2013/044800 WO2013185084A1 (en) 2012-06-08 2013-06-07 Pyrimidinyl tyrosine kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017150480A Division JP2017193583A (ja) 2012-06-08 2017-08-03 ピリミジニルチロシンキナーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2015518903A JP2015518903A (ja) 2015-07-06
JP2015518903A5 true JP2015518903A5 (enExample) 2016-07-28
JP6214643B2 JP6214643B2 (ja) 2017-10-18

Family

ID=49712704

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015516256A Expired - Fee Related JP6214643B2 (ja) 2012-06-08 2013-06-07 ピリミジニルチロシンキナーゼ阻害剤
JP2017150480A Withdrawn JP2017193583A (ja) 2012-06-08 2017-08-03 ピリミジニルチロシンキナーゼ阻害剤
JP2019017850A Withdrawn JP2019077728A (ja) 2012-06-08 2019-02-04 ピリミジニルチロシンキナーゼ阻害剤
JP2021018127A Pending JP2021073298A (ja) 2012-06-08 2021-02-08 ピリミジニルチロシンキナーゼ阻害剤
JP2021018128A Pending JP2021073299A (ja) 2012-06-08 2021-02-08 ピリミジニルチロシンキナーゼ阻害剤
JP2023004462A Pending JP2023052415A (ja) 2012-06-08 2023-01-16 ピリミジニルチロシンキナーゼ阻害剤

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017150480A Withdrawn JP2017193583A (ja) 2012-06-08 2017-08-03 ピリミジニルチロシンキナーゼ阻害剤
JP2019017850A Withdrawn JP2019077728A (ja) 2012-06-08 2019-02-04 ピリミジニルチロシンキナーゼ阻害剤
JP2021018127A Pending JP2021073298A (ja) 2012-06-08 2021-02-08 ピリミジニルチロシンキナーゼ阻害剤
JP2021018128A Pending JP2021073299A (ja) 2012-06-08 2021-02-08 ピリミジニルチロシンキナーゼ阻害剤
JP2023004462A Pending JP2023052415A (ja) 2012-06-08 2023-01-16 ピリミジニルチロシンキナーゼ阻害剤

Country Status (30)

Country Link
US (6) US9394277B2 (enExample)
EP (3) EP3385263B1 (enExample)
JP (6) JP6214643B2 (enExample)
KR (4) KR102102587B1 (enExample)
CN (3) CN109305959B (enExample)
AR (1) AR091273A1 (enExample)
AU (5) AU2013271407B2 (enExample)
BR (2) BR112014030655B1 (enExample)
CA (2) CA2875799C (enExample)
CY (1) CY1120638T1 (enExample)
DK (1) DK2858499T3 (enExample)
EA (2) EA027823B1 (enExample)
ES (2) ES2834333T3 (enExample)
HR (1) HRP20181294T1 (enExample)
HU (1) HUE039897T2 (enExample)
IL (2) IL235938B (enExample)
IN (1) IN2014DN10576A (enExample)
LT (1) LT2858499T (enExample)
MX (2) MX363672B (enExample)
NZ (1) NZ702715A (enExample)
PH (2) PH12018501463B1 (enExample)
PL (1) PL2858499T3 (enExample)
PT (1) PT2858499T (enExample)
RS (1) RS57978B1 (enExample)
SG (2) SG11201408173WA (enExample)
SI (1) SI2858499T1 (enExample)
SM (1) SMT201800442T1 (enExample)
TW (3) TWI592406B (enExample)
WO (1) WO2013185084A1 (enExample)
ZA (1) ZA201409255B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2771822C (en) * 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
US9353087B2 (en) 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
SG11201604595VA (en) * 2013-12-11 2016-07-28 Biogen Ma Inc Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2015151006A1 (en) 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
WO2015170266A1 (en) 2014-05-07 2015-11-12 Lupin Limited Substituted pyrimidine compounds as btk inhibitors
PT3461821T (pt) * 2014-10-24 2020-08-05 Bristol Myers Squibb Co Compostos de indol carboxamida úteis como inibidores de quinase
JP7214632B2 (ja) 2016-07-21 2023-01-30 バイオジェン エムエー インク. ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
WO2019208805A1 (ja) 2018-04-27 2019-10-31 小野薬品工業株式会社 Btk阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および/または治療剤
JP7286755B2 (ja) 2018-07-31 2023-06-05 ロクソ オンコロジー, インコーポレイテッド (s)-5-アミノ-3-(4-((5-フルオロ-2-メトキシベンズアミド)メチル)フェニル)-1-(1,1,1-トリフルオロプロパン-2-イル)-1h-ピラゾール-4-カルボキサミドの噴霧乾燥分散体および製剤
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
US20240216330A1 (en) 2021-04-02 2024-07-04 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023081709A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Vecabrutinib for the treatment of graft-versus-host disease
US20250074911A1 (en) 2021-12-14 2025-03-06 Crossfire Oncology Holding B.V. Macrocyclic btk inhibitors
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1624A (en) * 1840-06-10 Cooking-stove
US4528138A (en) 1984-06-20 1985-07-09 E. R. Squibb & Sons, Inc. 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6919178B2 (en) 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
SK13072002A3 (sk) 2000-03-17 2003-08-05 Bristol-Myers Squibb Pharma Company Deriváty cyklických beta-aminokyselín ako inhibítory matrixových metaloproteáz a TNF-alfa
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
PL359563A1 (pl) 2000-06-26 2004-08-23 Pfizer Products Inc. Związki pirolo [2,3-d] pirymidynowe jako środki immunosupresyjne
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
US20050143372A1 (en) * 2001-10-30 2005-06-30 Shomir Ghosh Compounds, pharmaceutical compositions and methods of use therefor
CA2464934A1 (en) 2001-10-31 2003-05-08 Bayer Healthcare Ag Pyrimido [4,5-b] indole derivatives
KR101078098B1 (ko) 2003-01-14 2011-10-28 아레나 파마슈티칼스, 인크. 대사 조절제로서의 1,2,3-삼치환된 아릴 및 헤테로아릴유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된장애의 예방 및 치료
ES2344007T3 (es) 2003-10-14 2010-08-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibidores proteina quinasa.
WO2006073419A2 (en) * 2004-04-01 2006-07-13 Gang Zheng Lipoprotein nanoplatforms
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス, インコーポレイテッド キナーゼ調節因子および使用方法
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
TW200621760A (en) 2004-09-09 2006-07-01 Mitsubishi Pharma Corp 2-morpholino-4-pyrimidone compound
EP1812440B1 (en) * 2004-11-04 2010-09-22 Vertex Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
MX2007006695A (es) 2004-12-03 2007-08-14 Schering Corp Piperazinas sustituidas como antagonistas de cb1.
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス, インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター(p70S6K、Akt−1およびAkt−2)としての[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジンまたは[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジン化合物
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
NZ567851A (en) 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
JP2009521445A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション H3アンタゴニスト/逆アゴニストと食欲抑制剤との組み合わせ
US20080076924A1 (en) 2006-06-30 2008-03-27 Patrick Betschmann Piperazines as P2X7 antagonists
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
KR20090046872A (ko) 2006-07-26 2009-05-11 노파르티스 아게 운데카프레닐 피로포스페이트 합성효소의 억제제
EP2270200A3 (en) * 2006-09-11 2011-07-13 CGI Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
AU2009243094B2 (en) 2006-11-06 2015-02-12 Massachusetts Institute Of Technology Immunomodulating compositions and methods of use thereof
TW200840571A (en) * 2007-03-02 2008-10-16 Schering Corp Piperidine derivatives and methods of use thereof
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
CN101932580B (zh) 2007-06-01 2013-05-22 葛兰素史密丝克莱恩有限责任公司 咪唑并吡啶激酶抑制剂
WO2009098144A1 (en) 2008-02-05 2009-08-13 F. Hoffmann-La Roche Ag Novel pyridinones and pyridazinones
CN105362277A (zh) 2008-07-16 2016-03-02 药品循环有限公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
WO2010068788A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
BRPI0922565A2 (pt) 2008-12-19 2015-12-15 Bristol Myers Squibb Co compostos de carbazol carboxamida úteis como inibidores de cinase
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
WO2010136423A1 (de) 2009-05-25 2010-12-02 Sandoz Ag Verfahren zur herstellung von ceftobiprol medocaril
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYL-BTK INHIBITORS
CA2771822C (en) 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
US8685880B2 (en) 2010-06-30 2014-04-01 Chevron U.S.A. Inc. On-site drying of aqueous salt for ionic liquid make-up
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
US9353087B2 (en) 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
SG11201604595VA (en) 2013-12-11 2016-07-28 Biogen Ma Inc Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
EP3080122B1 (en) 2013-12-11 2018-10-31 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2016054627A1 (en) 2014-10-03 2016-04-07 Ohio State Innovation Foundation Biomarkers of bruton tyrosine kinase inhibitor resistance
JP7214632B2 (ja) * 2016-07-21 2023-01-30 バイオジェン エムエー インク. ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物

Similar Documents

Publication Publication Date Title
JP2015518903A5 (enExample)
CY1124222T1 (el) Ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με μεθυλο/φθορο-πυριδινυλο-μεθοξυ και ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με φθορο-πυριδινυλο-μεθοξυ
JP2016539996A5 (enExample)
MX2022005399A (es) Compuestos.
JP2011046700A5 (enExample)
RU2017125025A (ru) Конденсированные кольцевые гетероарильные соединения и их применение в качестве ингибиторов trk
JP2017536369A5 (enExample)
JP2016536363A5 (enExample)
JP2015535277A5 (enExample)
JP2015181191A5 (enExample)
BR112017011731A2 (pt) compósito, processo para produção de compósito, catalisador de síntese de amônia e processo de síntese de amônia
RU2017120274A (ru) Гетероарильные соединения в качестве ингибиторов irak и их применения
JP2010535722A5 (enExample)
JP2017524733A5 (enExample)
EA201600373A1 (ru) ПИРРОЛО[2,3-d]ПИРИМИДИНИЛ-, ПИРРОЛО[2,3-b]ПИРАЗИНИЛ- И ПИРРОЛО[2,3-d]ПИРИДИНИЛАКРИЛАМИДЫ
PH12015500294A1 (en) Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
JP2019081762A5 (enExample)
JP2019519587A5 (enExample)
JP2017518323A5 (enExample)
JP2012097115A5 (enExample)
JP2015091935A5 (enExample)
JP2014526533A5 (enExample)
JP2013147490A5 (ja) イリジウム錯体
JP2017515919A5 (enExample)
JP2015510508A5 (enExample)